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E-mail: valeria.poli@unito.itMyocarditis can lead to autoimmune disease, dilated cardiomy-
opathy, and heart failure, which is modeled in the mouse by
cardiac myosin immunization (experimental autoimmune
myocarditis [EAM]). Signal transducer and activator of tran-
scription 3 (STAT3) systemic inhibition exerts both preventive
and therapeutic effects in EAM, and STAT3 constitutive activa-
tion elicits immune-mediated myocarditis dependent on com-
plement C3 and correlating with activation of the STAT3-inter-
leukin 6 (IL-6) axis in the liver. Thus, liver-specific STAT3
inhibition may represent a therapeutic option, allowing to
bypass the heart toxicity, predicted by systemic STAT3 inhibi-
tion. We therefore decided to explore the effectiveness of
silencing liver Stat3 and C3 in preventing EAM onset and/or
the recovery of cardiac functions. We first show that comple-
ment C3 and C5 genetic depletion significantly prevents the
onset of spontaneous myocarditis, supporting the complement
cascade as a viable target. In order to interfere with comple-
ment production and STAT3 activity specifically in the liver,
we took advantage of liver-specific Stat3 or C3 small interfering
(si)RNA nanoparticles, demonstrating that both siRNAs can
significantly prevent myocarditis onset and improve the recov-
ery of heart functions in EAM. Our data demonstrate that liver-
specific Stat3/C3 siRNAs may represent a therapeutic option
for autoimmune myocarditis and suggest that complement
levels and activation might be predictive of progression to
dilated cardiomyopathy.
INTRODUCTION
Myocarditis is an inflammatory heart disease in which its etiology is
often linked to infection with viral pathogens exhibiting a direct
myopathic effect. It can cause acute or chronic heart failure and prog-
ress to dilated cardiomyopathy (DCM) in susceptible individuals
(about 30% of patients), representing a relatively frequent cause of
cardiac failure, particularly in young adults.1 Nevertheless, the basis
for differential susceptibility to disease progression is not yet under-62 Molecular Therapy: Methods & Clinical Development Vol. 18 Septem
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and cluster of differentiation 4+ (CD4+) T lymphocytes, and the dis-
ease is characterized by a potent T cell-mediated immune response
sustaining high titers of autoantibodies against heart proteins.2
Although the autoimmune pathogenesis of the chronic disease is
widely accepted, despite the success obtained with immunosuppres-
sant therapies in a subset of patients,3,4 no such therapeutic protocol
has yet been formally approved.
Immune-mediated myocarditis is mainly modeled in susceptible
strains of mice by experimental autoimmune myocarditis (EAM),5,6
where immunization with an alpha-myosin peptide, emulsified with
complete Freund’s adjuvant, triggers an initial acute activation of
innate immunity.7 This consists of abundant leukocyte infiltration
in the myocardium, which is, in turn, required for the ensuing
adaptive immune response.7,8 Adaptive immunity is mainly driven
by antigen-specific T cells and characterized by significant self-reac-
tive antibodies production and immunoglobulin (Ig) deposition on
cardiac cells,8 correlating with the onset and progression of systolic
dysfunction that can be assessed by echocardiography.7,9 EAM
studies, making use of inhibitors and of genetically modified mice,
have demonstrated the pathogenic role of several cytokines and
complement components,7 serving as hypothesis-generating results
for the human disease. For example, the inflammatory cytokine inter-
leukin 6 (IL-6), which was shown to increase the number of cardiac
myosin autoreactive CD4+ T cells,8 plays a key role in EAM, since
IL-6 null mice are protected from myocarditis development,ber 2020 ª 2020 The Author(s).
//creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Genetic Depletion of Complement C3 and
C5 Rescues Myocarditis in Stat3C/C Mice
Mortality was recorded in mice of the indicated geno-
types, followed by analysis of myocarditis-related pa-
rameters in the serum and heart. Genotypes: wild-type
(WT) or homozygous for the Stat3C allele (S3WT/WT,
S3C/C), either sufficient or deficient for the indicated
complement genes, C3/,+/+ or C5/,+/+. (A) Kaplan
Meyer curve of mice of the indicated genotypes. Log rank
Mantel-Cox test, p values: S3C/C/C3+/+/C5+/+ versus
S3C/C/C3//C5/, p < 0.0001; S3C/C/C3+/+/C5+/+
versus S3C/C/C3//C5+/+, p = 0.0099; S3C/C/C3+/+/
C5+/+ versus S3C/C/ C3+/+/C5/, p = 0.0011; S3C/C/
C3//C5+/+ versus S3C/C/C3//C5/, p = 0.0008;
S3C/C/C3+/+/C5/ versus S3C/C/C3//C5/, p =
0.0490; n: S3WT/WT/C3+/+/C5+/+ (black line), n = 64;
S3C/C/C3+/+/C5+/+ (gray line), n = 14; S3C/C/C3//C5+/+
(red line), n = 16; S3C/C/C3+/+/C5/ (blue line), n = 50;
S3C/C/C3//C5/ (green line), n = 27. (B) Serum anti-
myosin IgG1 autoantibodies measured by ELISA at sac-
rifice in mice wild-type (empty bars, values below
threshold), Stat3C/C diseased (filled bars), or healthy
(striped bars), carrying inactivated () C3 (red bars), C5
(blue bars), or both (green bars) genes. Data are mean ±
SEM of the indicated values. n.d., not detected. Mann-
Whitney U test, p values: ****p < 0.0001. (C) SerumC3ameasured by ELISA in the mice described in (B). (D) SerumC5a wasmeasured as described in (C). (C and D) Data
are mean ± SEM of the indicated values. n.d., not detected. Unpaired two-tailed Student’s t test with Welch’s correction: *p < 0.05; **p < 0.01.
www.moleculartherapy.orgcorrelating with reduced complement C3 expression and heart
deposition.10 Indeed, C3 is thought to promote EAM by activating
mast cells and macrophages, triggering, in turn, autoreactive T and
B cells.7,11 Complement depletion by means of cobra venom factor
or inactivation of the CR1/2 C3 receptor genes impairs EAM induc-
tion by globally decreasing the levels of tumor necrosis factor a
(TNF-a), IL-1b, and anti-myosin autoantibodies, as well as T helper
cell type 1 (Th1)- and Th2-type immune responses.12 IL-6, together
with transforming growth factor b (TGF-b), is the major driver of
Th17 cell differentiation via the activation of the transcription factor
signal transducer and activator of transcription 3 (STAT3),13,14 and
indeed, Th17-type responses are a key adaptive immunity feature in
EAM, playing a major role in postmyocarditis remodeling and
DCM development.15,16
We have recently shown that STAT3 systemic inhibition could not
only prevent EAM development but also therapeutically improve
heart function when administered at the inflammation peak.17 More-
over, ubiquitous expression of constitutively active STAT3 (STAT3C)
in genetically modified Stat3C/C mice was sufficient to elicit the devel-
opment of an immune-mediated form of myocarditis, reminiscent of
EAM, involving the activation of a STAT3-IL-6 axis, specifically in the
liver. This conclusion was supported by increased hepatic-specific
expression of the IL-6 receptor (IL-6R), in which its blockage by
means of neutralizing antibodies could significantly impair the devel-
opment of heart inflammation and autoimmunity.17 Here, we show
that complement C3 and C5 genetic depletion significantly blunts
myocarditis in the Stat3C/C mice, strongly supporting the pathogenic
role of complement. Next, we set out to demonstrate our hypothesisMolecular Ththat myocarditis development in the Stat3C/C mice may be triggered
by the observed enhancement of IL-6 signaling in the liver, presum-
ably via overproduction of complement components and comple-
ment-activating, acute-phase proteins. In order to prove this hypoth-
esis, we generated liver-specific small interfering RNA (siRNA)
lipidoid particles and show that interference with either STAT3 or
C3 expression in the liver exerts both protective and therapeutic ef-
fects in EAM, confirming the involvement of liver inflammation in
autoimmune myocarditis and suggesting a potential novel liver-tar-
geted strategy for therapeutic intervention also in patients.
RESULTS
C3 and C5 Genetic Depletion Partially Rescues Myocarditis in
Stat3C/C Mice
In order to further explore the role of complement in the immune-
mediated myocarditis developing in the Stat3C/C mice, we inter-
crossed them with mice carrying null alleles for the C3 gene,18 the
C5 gene,19 or both, generating Stat3C/C/C3/, Stat3C/C/C5/, and
Stat3C/C/C3//C5/ compound mutant mice. Although C3 genetic
depletion significantly delayed disease development as compared with
Stat3C/C mice (Figure 1A; compare gray and red lines), all Stat3C/C/
C3/ mice eventually developed myocarditis and succumbed to
the disease, displaying high levels of anti-myosin antibodies and of
myeloid heart infiltration (Figures 1B and 2A). Figure S1 shows the
gating used to analyze the flow cytometry data of Figure 2A. Despite
the complete absence of C3, the circulating levels of activated C5 were
equivalent in Stat3C/C/C3/ mice and their C3-sufficient littermates
(Figure 1D), suggesting activation of the complement cascade even in
the absence of C3, as previously reported.20 In contrast, inactivationerapy: Methods & Clinical Development Vol. 18 September 2020 63
Molecular Therapy: Methods & Clinical Developmentof the C5 gene led to the survival of 28% of the Stat3C/C/C5/ mice
(Figure 1A; blue line). Surviving mice (hereafter denominated
“healthy”) showed very little anti-myosin antibodies and a number
of heart-infiltrating myeloid cells similar to wild-type mice (Figures
1B and 2A; striped bars), whereas mice succumbing to the disease
(hereafter denominated “diseased”) were indistinguishable from their
C5-sufficient Stat3C/C littermates for these parameters, as well as for
the serum levels of activated C3 (Figures 1B, 1C, and 2A; filled
bars). Interestingly, the inactivation of both the C3 and C5 genes trig-
gered a synergic effect, affording protection from myocarditis to 52%
of the mice (Figure 1A; green line). Similar to the C5/mice, healthy
C3//C5/ double-mutant Stat3C/C mice displayed very low anti-
myosin antibodies and no heart infiltration (Figures 1B and 2A;
striped bars). Both features were instead similar to those of their
C3, C5-sufficient Stat3C/C controls (CTRLs) in diseased mice (Figures
1B and 2A; filled bars). Confirming the null phenotype, neither acti-
vated C3 nor C5 was detectable in the double-mutant mice (Figures
1C and 1D). These results were confirmed by heart immunohisto-
chemical analysis in mice of the different genotypes (Figures 2B
and 2C). In keeping with the above observations, whereas diseased
mice of all genotypes (Stat3C/C, Stat3C/C/C3/, Stat3C/C/C5/, and
Stat3C/C/C3//C5/) displayed abundant infiltration and heart
fibrosis, as revealed by anti-CD18 and collagen 1 and 3 picrosirius
staining, respectively, the hearts of surviving Stat3C/C/C5/ and
Stat3C/C/C3//C5/ mice were indistinguishable from their wild-
type CTRLs.
Liver-Specific Knockdown of Either C3 or STAT3 Significantly
Impairs Myocarditis Development in Stat3C/C Mice
Since our genetic experiments unequivocally demonstrated the cen-
tral role of the complement system in the pathogenesis of immune-
mediated myocarditis in Stat3C/C mice, we decided to test the hy-
pothesis that STAT3 activity and complement C3 hyperproduction
in the liver are crucial for disease development. To this end, we
generated anti-murine C3 or Stat3 siRNAs, appropriately modified
to improve their stability, and assembled them with lipidoid parti-
cles suitable for in vivo delivery. Due to the size and other physico-
chemical characteristics of the nanoparticles, this formulation is re-
ported to specifically deliver its cargo to tissues characterized by
fenestrated capillaries and particularly to the liver upon systemic
administration.21–23 As shown in Figure S2, both C3 and Stat3
siRNAs triggered significant downregulation of the respective
mRNA in the liver but not in the spleen, heart, or whole blood.
Moreover, the Stat3 siRNA also significantly reduced hepatic C3
mRNA levels, confirming STAT3 dependency of liver C3 expres-
sion. Strikingly, when administered to Stat3C/C newborn mice,
both siRNA formulations were able to abolish myocarditis develop-
ment in more than 50% of the mice compared to a CTRL-unrelated
siRNA, as shown by the KaplanMeyer curve of Figure 3A. Similar to
what was already observed with C3 and C5 genetic depletion and
previously with IL-6R or complement neutralization,17 we noticed
an “all or nothing” effect. Whereas the mice developing the disease
displayed high anti-myosin antibody levels, abundant heart infiltra-
tion, and consistent fibrotic damage, similar to those treated with64 Molecular Therapy: Methods & Clinical Development Vol. 18 Septemthe CTRL siRNA (Figures 3B and 3C), healthy mice never devel-
oped detectable anti-myosin IgGs, inflammatory infiltration, or
fibrosis.
Liver Knockdown of Either C3 or STAT3 Prevents Myocarditis
Development in the EAM Model
We have previously demonstrated that systemic STAT3 inhibition
could both prevent and partially cure myocarditis and heart failure
in the EAM model.17 In order to test whether specific inhibition of
STAT3 activity in the liver could elicit similar effects and to assess
the role of liver-produced C3, we triggered EAM in BALB/c mice
and silenced either Stat3 or C3 mRNAs with their specific lipidoid-
siRNA nanoparticles, starting from the day of immunization (Fig-
ure 4A). As expected, at the end of the experiment, cardiac contrac-
tility was severely impaired in mice treated with a CTRL siRNA, as
evidenced by a significant reduction of fractional shortening (FS)
and ejection fraction (EF), respectively, compared to day 0 (Figures
4B and 4C; empty gray bars). Strikingly, mice treated with either
siC3 or siStat3 had instead completely preserved FS and EF at day
28 (Figures 4B and 4C; filled orange or purple bars, respectively),
demonstrating that both siRNAs prevent the development of systolic
dysfunction. Accordingly, anti-myosin antibodies were much less
abundant in mice treated with either siRNA (Figure S3). Circulating
C3 was undetectable upon liver C3 silencing until day 21, when the
siRNA effects started to decrease, leading to C3 levels comparable
to the CTRLs at day 28 (Figure S3).
Liver Knockdown of Either C3 or STAT3 Can Therapeutically
Alleviate Myocarditis in EAM Mice
In order to assess the therapeutic potential of liver STAT3 or C3
neutralization, the siRNA treatments were started at day 21 (C3)
or 28 (Stat3) of the EAM protocol, depending on when systolic
dysfunction was first detected (Figure 5A). Strikingly, heart contrac-
tility improved much quicker upon treatment with both siRNAs as
compared to CTRL-treated mice (Figures 5B and 5C). Whereas in
animals treated with siCTRL, systolic dysfunction persisted until
the end of the experiment (day 42; Figures 5B and 5C; empty gray
bars), and treatment with siC3 completely restored cardiac contrac-
tility to the physiological day 0 levels already by day 28, i.e., after
1 week of treatment (Figure 5B; filled orange bars). In Stat3
siRNA-treated mice (Figure 5C; filled purple bars), the recovery of
both FS and EF was slower and became evident 2 weeks after the
start of the treatment (day 42). Together with the results of the pre-
ventive protocol, our experiments clearly show that activity and
expression of both Stat3 and C3 in the liver are crucial in the devel-
opment and progression of EAM, with potentially profound impli-
cations also for the human disease.
DISCUSSION
Myocarditis is a complex disease with different therapeutic options
depending on the etiology and on histological, microbiological,
and immune features.4,24 In particular, it can be classified as the
following (1) viral, when histological evidence of myocarditis is
coupled to viral genome detection, amenable to antiviral drugber 2020
Figure 2. Reduced Heart Infiltration and Damage in Healthy C5–/– and C3–/–/C5–/– Stat3C/C Mice
Heart infiltration was analyzed by flow cytometry and immunohistochemistry in mice of the different genotypes, described in Figure 1, either healthy (striped bars) or diseased
(filled bars). (A) Heart-infiltrating CD11b+ cells, either positive or negative for Gr1, were analyzed by flow cytometry. Data are mean ± SEM of the indicated values. Mann-
Whitney U test, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant. (B) Hearts were dissected, formalin fixed, sectioned, and analyzed by hematoxylin and
eosin (H&E), CD18 antibody (pan-monocyte marker), or picrosirius red staining (collagen 1 and 3). Scale bars, 100 mm. Representative samples are shown. (C) The infiltrated
area wasmeasured onH&E sections in at least 3mice/group and expressed as percentage of heart area, as described inMaterials andMethods. Data aremean ±SEM of the
indicated values. n.d., not detected. Unpaired two-tailed Student’s t test with Welch’s correction, *p < 0.05; **p < 0.01, ****p < 0.0001.
www.moleculartherapy.orgtreatment; (2) autoimmune, i.e., viral negative, with or without
circulating cardiac antibodies, where immunosuppressant
therapies have shown efficacy;3,4 or (3) viral and autoimmune,
positive both for cardiac antibodies and virus. Among the
outstanding questions in myocarditis pathogenesis are the deter-
minants of progression to chronic autoimmune disease, whichMolecular Thoccurs in about 30%–40% of patients, and the identification of
therapeutic options for viral and autoimmune myocarditis, where
immunosuppression is not applicable.3,4 A better understanding of
the pathogenetic mechanisms and of the molecules involved is
therefore crucial to help to identify novel personalized, therapeutic
approaches.erapy: Methods & Clinical Development Vol. 18 September 2020 65
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required for the inductive phase of EAM. Accordingly, our genetic ex-
periments support a role for complement in the pathogenesis of the
immune-mediated myocarditis in Stat3C/Cmice. However, C3 genetic
depletion in these mice only delays disease onset without affecting its
morbidity. Despite the absence of C3, however, activated C5a can be
detected at similar concentrations in both C3-null and C3-sufficient
Stat3C/C mice, suggesting that C5 activation, which has already
been proposed to occur in the C3 null mice as a compensatory mech-
anism,20 is involved in disease development. In keeping with this
observation, C5 gene inactivation leads to a more significant delay
in myocarditis onset, completely protecting about 25% of the mice.
Disease protection more than doubles in the C3, C5 double-mutant
mice, supporting the view that both C3 and C5 activations are
involved and suggesting a role for both C3 and C5 anaphylotoxins
in addition to the complement cascade.
Our working hypothesis proposed that amplification of IL-6 signaling
with constitutive STAT3 activation in the liver plays a major role in
myocarditis development of the Stat3C/C mice.17 The present study
formally proves this view, since abolishing STAT3 liver expression
by means of a systemically delivered hepato-specific siRNA was suf-
ficient to significantly protect mice from myocarditis development.
Also, liver-specific C3 silencing was effective in blocking disease
development, demonstrating that C3 excessive production in the
liver, downstream of STAT3 activation, is involved in triggering
myocarditis in these mice. Under this regard, C3 silencing was
actually strikingly more effective than C3 gene inactivation, probably
due to the well-known phenomenon of genetic compensation.25
We have previously shown that in vivo systemic inhibition of STAT3
was sufficient to both prevent disease development and exert thera-
peutic effects in the EAM model.17 Strikingly, our experiments
show that the pathogenic role of STAT3 mainly takes place in the
liver, not only in the Stat3C/C mice but also in EAM, since the hep-
ato-specific Stat3 siRNA acted similarly to the systemic inhibitor in
impairing myocarditis onset and in ameliorating cardiomyopathy.
Remarkably, the targeting of STAT3-activated liver C3 with a similar
siRNA formulation also exerted both preventive and therapeutic ef-
fects, in partial contrast with previous data suggesting that C3 pro-
duction is only fundamental in the early phases of EAM onset.12
This discrepancy might be due to the different strains and treatments
used, CR/ or +/+ A/J mice, and cobra venom factor in the cited study
versus C3/ or +/+ BALB/c mice and liver-specific siRNAs here.
The link between dysregulation of liver activities and heart inflamma-
tion/autoimmunity might well be relevant also in patients, since we
have previously shown that IL-6, the main STAT3 activator, as well
as C3 and C-reactive protein (CRP), which is universally used in
the clinics as an inflammation marker and is capable of activating
the complement system, are elevated in the blood of myocarditis pa-
tients.17 Interestingly, IL-6 and STAT3 play a fundamental role in
the activation of the liver acute-phase response (APR),26 which is
triggered by both systemic and localized inflammation and consists66 Molecular Therapy: Methods & Clinical Development Vol. 18 Septemof the upregulation of many liver-produced plasma proteins involved
in innate immunity, including several complement components and
CRP.27,28 In light of this knowledge, since the liver APR is profoundly
implicated in the correct development of acquired immunity, the un-
expected link that we observed between liver STAT3 activity and the
development of immune-mediated myocarditis is perhaps not too
surprising and might be worth exploring in other autoimmune dis-
eases, where both IL-6 and STAT3 have been amply, functionally
implicated.29 Importantly, STAT3 is known to exert a protective
role in the heart,30 suggesting that its systemic inhibition, particularly
in heart disease, might compromise cardiomyocyte survival and func-
tion and may not be suitable to treat myocarditis. Additionally,
although efficient STAT3 inhibitors have been the object of intense
research for years, so far, no lead molecule has reached the clinic.
In this context, liver-specific siRNA delivery is an attractive approach,
since our particle formulation is analogous to that of Onpattro (pati-
siran), the first-ever siRNA-based drug approved.31 Indeed, transcrip-
tion factors are traditionally considered undruggable due to their
nuclear localization and the lack of enzymatic activity that could be
targeted by small molecules.32 In contrast an siRNA-mediated
approach, targeting not the protein but its mRNA, has the potential
to be extremely effective. Another viable option is offered by the effec-
tiveness of the liver C3 siRNA. Indeed, the systemic inhibition of
complement functions might be toxic by interfering with native
and acquired immunity, whereas the abolishment of C3 production,
specifically in the liver, not affecting the other sources of complement
proteins, should not exert a generic, immunosuppressive effect and
might be a particularly appealing approach for patients with viral
and autoimmune myocarditis, where immunosuppression is not
supported. One could even envisage combined C3 and Stat3
siRNA-mediated targeting to increase the effectiveness of the treat-
ment. Although the administration of Onpattro in patients is accom-
panied with a cocktail of anti-inflammatory drugs at the time of treat-
ment, to reduce the risk of infusion-related reactions observed with
other liposomal products,33 it is unlikely that these drugs may alter
the overall efficacy of the Stat3 and C3 siRNAs, which are expected
to be long lasting. Indeed, we did not detect any sign of toxicity,
including body weight loss, in any of the EAM groups.
The nonredundant pathogenic role that we have uncovered for liver-
produced complement factors in myocarditis pathogenesis is in line
with the well-known complement vital functions in both coronary
disease and heart failure. Our data suggest that high levels of comple-
ment proteins, in particular, C3, and of complement activation, either
of reactive origin or genetically determined, may serve as biomarkers
to predict the progression from acute to chronic myocarditis.4 In
keeping with this idea, C3, C3a, C5, and Membrane Attack
Complex (MAC) complex levels are known to correlate with systemic,
low-grade inflammation.34 Our findings are therefore compatible
with the hypothesis that a pre-existing, even undetected inflammatory
condition, raising IL-6 activity, may trigger constitutive liver STAT3
activation and consequent initiation of the APR. This would result in
increased circulating levels of complement factors and other APR
proteins, such as CRP, which may facilitate complement activationber 2020
Figure 3. siRNA-Mediated Liver-Specific Downregulation of C3 or Stat3 Can Prevent Myocarditis in Stat3C/C Mice
Newborn Stat3C/C mice were injected i.p. (from postnatal day 0 to 21) and then i.v. every 3 days with siRNA control (CTRL), against C3 or against Stat3, followed by serum
withdrawal and heart analysis, as described below. (A) The Kaplan Meyer curve shows survival of Stat3C/C mice injected with siRNA CTRL (gray line, n = 26), against C3
(orange line, n = 9) or against Stat3 (purple line, n = 7). Log rankMantel-Cox test, p values: CTRL siRNA versus C3 siRNA, ***p < 0.001; CTRL siRNA versus Stat3 siRNA, **p <
0.01. (B) Serum anti-myosin IgG1 autoantibodies weremeasured by ELISA inmice treated with CTRL siRNA (gray bar); C3 siRNA, either diseased (filled orange bar) or healthy
(striped orange bar); and Stat3 siRNA, either diseased (filled purple bar) or healthy (striped purple bar). Data are mean ± SEM. Unpaired two-tailed Student’s t test with
Welch’s correction,: **p < 0.01; ***p < 0.001. (C) The hearts of mice belonging to the above groups were sectioned and analyzed by H&E, CD18 antibody (pan-monocyte
marker), or picrosirius red staining (collagen 1 and 3). Scale bars, 100 mm.
www.moleculartherapy.organd deposition in a heart, potentially already damaged by viral infec-
tion, and help start autoimmunity and chronic heart inflammation.
Further work analyzing patients at the time of symptoms onset, dur-
ing therapy and after recovery, is required to support the feasibility
of translating our therapeutic protocols to the clinic. In particular,
the systemic and local levels of complement proteins, such as C3,
C5, C3a, and C5a; their deposition on heart tissue; and the concen-
trations of IL-6 and CRP, will have to be assessed and analyzed with
reference with the clinical history of the patient, keeping also intoMolecular Thaccount the differences between the murine and human comple-
ment systems.35 We predict that our protocol may represent a
much-needed therapeutic option for those patients with viral and




Generation of the Stat3C/C mice was previously described.36 Mice
were crossed for 8 generations in the BALB/c background. C3/erapy: Methods & Clinical Development Vol. 18 September 2020 67
Figure 4. C3 or Stat3 siRNA Treatment Prevents EAM Development in BALB/c Mice
(A) Schematic representation of the experiment. BALB/c mice were immunized with an alpha-myosin peptide; treated i.v. every 3 days with CTRL or specific siRNAs, starting
from day 0; and sacrificed at day 28. (B and C) Echocardiographic analyses were performed at the indicated days postimmunization, followed by calculation of the fractional
shortening (FS) and ejection fraction (EF). Selected Doppler images are shown at day 0 (untreated CTRLs) and day 28 after immunization. The histograms showmean ± SEM
values of 6 mice/group. Statistical differences were calculated by two-way ANOVA on repeated measures with Bonferroni post-test. + indicates differences between day
0 and the indicated time points of the same siRNA treatment; * indicates differences between CTRL and specific siRNA groups at the indicated time point. +, *p < 0.05; ++,
**p < 0.01; +++p < 0.001. Tables below the histograms report the percentages of FS and EF, calculated at each time point, with respect to the values at day 0. (B) Mice were
injected with either CTRL (siCTRL, empty gray bars) or C3 siRNA (siC3, filled orange bars). (C) Mice were injected with either CTRL (siCTRL, empty gray bars) or Stat3 siRNA
(siStat3, filled purple bars).
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Figure 5. C3 or Stat3 siRNA Treatment Rescues Systolic Dysfunction in EAM.
(A) Schematic representation of the experiment. BALB/c mice were immunized with an alpha-myosin peptide as in Figure 4; injected i.v. with CTRLs or specific siRNAs every
3 days starting from day 21 (C3, B) or 28 (Stat3, C), when echocardiographic analyses showed systolic dysfunction; and sacrificed at day 42. (B and C) Echocardiographic
analyses were performed at the indicated times (days postimmunization), followed by calculation of the FS and EF. Selected Doppler images are shown at day 0 (untreated
CTRLs) and day 28 and day 42 after immunization. The histograms showmean ± SEM of the values. Statistical differences were calculated by two-way ANOVA on repeated
measures with Bonferroni post-test. + indicates differences between day 0 and the indicated time points of the same siRNA treatment; * indicates differences between CTRL
and specific siRNA groups at the indicated time point. +, *p < 0.05; ++, **p < 0.01; +++, ***p < 0.001; ++++, ****p < 0.0001. Tables below the histograms report the
percentages of FS and EF calculated at each time point with respect to the values at day 0. (B) Mice were injected with either CTRL (siCTRL, empty gray bars) or C3 siRNA
(siC3, filled orange bars). (C) Mice were injected with either CTRL (siCTRL, empty gray bars) or Stat3 siRNA (siStat3, filled purple bars).
www.moleculartherapy.organd C5/ mice were kindly supplied by Prof. Federica Cavallo
(University of Turin) and Marina Botto (Imperial College of Lon-
don). Mice were maintained in the transgenic unit of the Molecular
Biotechnology Center (University of Turin) under a 12-h light-dark
cycle and provided food and water ad libitum, inspected and weighed
every 3 days. Procedures were in conformity with national and inter-
national laws and policies, as approved by the Faculty Ethical
Committee.Molecular ThFlow Cytometry
To isolate infiltrating cells, hearts were disaggregated with collagenase
type 2 (cat. C6885; Sigma-Aldrich, St. Louis, MO, USA) and protease
type XIV (cat. P5147; Sigma-Aldrich, St. Louis, MO, USA), as
described.17 Cells were stained with fluorescein isothiocyanate
(FITC) anti-Gr1 (cat. 108405; BioLegend, San Diego, CA, USA)
and phycoerythrin (PE) anti-CD11b antibodies (cat. 101208; Bio-
Legend, San Diego, CA, USA), diluted 1:100 (30 mL per staining)erapy: Methods & Clinical Development Vol. 18 September 2020 69
Molecular Therapy: Methods & Clinical Developmentfor 20 min at 4C, and analyzed with a FACSCalibur flow cytometer
(BD Biosciences, Franklin Lakes, NJ, USA) and CellQuest software.
Experimental Autoimmune Myocarditis
8-week-old female BALB/c mice were immunized as described37 with
the alpha-myosin heavy-chain peptide (Myhc-alpha)614–634 (cat.
62554; AnaSpec, Fremont, CA, USA), emulsified 1:1 in Freund’s com-
plete adjuvant (CFA; cat. BD 263810; Difco Laboratories, Detroit, MI,
USA). In the preventive setting (Figure 4), siRNA lipidoid nanopar-
ticles were administered starting from the first day of immunization,
and disease progression was monitored by echocardiography. For the
therapeutic setting (Figure 5), all EAM mice were subjected to echo-
cardiography at days 21–28 to assess disease development. Mice
showing a reduction of at least 10% in EF and FS were recruited for
siRNA injection and randomized into the CTRL and treated groups
in order to obtain homogeneous cohorts. No animals were excluded
after starting the siRNA treatments in either protocol. Throughout
the entire experiments, mice weight was monitored, without the
observation of any weight loss or other visible signs of distress.
In Vivo siRNA-Containing Lipidoid Nanoparticle Treatment
Lipidoid siRNA formulations were developed by Alnylam Pharma-
ceuticals (Cambridge, MA) as described,22 using a three-component
systemic siRNA delivery system, based on the lipid-like material
C12-200,38 cholesterol, and the poly(ethylene glycol) (PEG) lipid
mPEG2000-C14 glyceride. Mouse reference sequences for Stat3
mRNA (GenBank: NM_213659) and C3 mRNA (GenBank:
NM_009778) were used for siRNA selection. Candidate siRNA se-
quences were subjected to a homology search against the RefSeq
mRNA database and ranked the most specific siRNAs against each
target for synthesis. Single-stranded RNAs were synthesized at Alny-
lam Pharmaceuticals on controlled pore glass using standard phos-
phoramidite chemistry as described elsewhere.39 The following
strands were used: C3 sense strand: cGAucAGuucAGucGAuuudTdT;
C3 antisense strand: AAAUCGACUGAACUGAUCGdTsdT; Stat3
sense strand: GccucAAGAuuGAccuAGAdTsdT; Stat3 antisense
strand: UCuAGGUcAAUCUUGAGGCdTsdT; CTRL sense strand:
cuuAcGcuGAGuAcuucGAdTsdT; CTRL antisense strand: UCGAA
GuACUcAGCGuAAGdTsdT; 20-OMe-modified nucleotides are in
lowercase; s is phosphorothioate linkage. The formulation developed
is hepato-specific (>90% injected dose distributes to liver) and can
induce fully reversible gene silencing. Newborn Stat3C/Cmice were in-
jected intraperitoneally (i.p.) with 1 mg/kg of C3, Stat3, or CTRL
siRNA-containing nanoparticles,22 every 3 days, starting from post-
natal days 1 to 21, and subsequently, intravenously (i.v.) with
0.1 mg/kg (C3) or 0.5 mg/kg (Stat3, CTRL). Diseased and healthy an-
imals were defined based on observational data (body weight loss,
body stance, activity, sudden death), followed by retrospective
serological and immunohistochemistry (IHC) analysis.
ELISA Assays
Anti-cardiac alpha-myosin IgG1 levels were measured upon coating
with 3 mg/mL of cardiac myosin, prepared as described,40 followed
by incubation with mouse sera and horseradish peroxidase (HRP)-70 Molecular Therapy: Methods & Clinical Development Vol. 18 Septemlabeled rat anti-mouse IgG1 (cat. 559626; BD Biosciences). Murine
C3 was captured with a polyclonal goat IgG to mouse C3 and revealed
with the same antibody peroxidase conjugated (cat. 55557; Cappel,
ICN Pharmaceuticals, Costa Mesa, CA, USA). SAP (serum amyloid
P) component, normal mouse standard (cat. 565193; Calbiochem,
San Diego, CA, USA), was used as a standard, according to the man-
ufacturer’s instructions. Circulating C3a and C5a levels were
measured using BD Biosciences assays (Franklin Lakes, NJ, USA),
according to the manufacturer’s instructions. Briefly, coating was
performed with 1.5 mg/mL (C3a, cat. 558250) and 2 mg/mL (C5a,
cat. 558027) antibodies overnight at 4C; then, diluted sera (1:2,000
for C3a; 1:50 for C5a) were incubated for 2.5 h at room temperature,
and biotinylated antibodies (C3a, cat. 558251; C5a, cat. 558028) were
used for detection of the assays, developed with a biotin-streptavidin
system (cat. 554066). Reference curves for C3a and C5a were made by
serial dilution of purified mouse recombinant proteins (cat. C3:
558618; C5a: 622597; Pharmingen, Franklin Lakes, NJ, USA).
Histological and Immunohistochemical Analysis
Hearts were fixed in 4% paraformaldehyde for 24 h and paraffin
embedded. Independent sections were produced as follows: 5 adjacent
6 mm sections were generated, followed by removal of a 50-mm-thick
portion of the paraffin sample block, generation of further 5 adjacent
6 mm sections, removal, and so on for at least 5 rounds. One random
section from each layer was then stained with hematoxylin and osin.
For immunohistochemistry, antigen retrieval on formalin-fixed
paraffin-embedded (FFPE) sections was performed with citrate buffer
(Sigma-Aldrich), and sections were then saturated (3% BSA + 5%
goat serum in Tris-buffered saline [TBS]); incubated overnight with
rat anti-mouse CD18 (cat. T-2122; BMA Biomedicals, Augst,
Switzerland), followed by biotinylated anti-rat IgG (cat. BA-2000;
Vector Laboratories) and avidin-biotin (ABC)-HRP complex (cat.
PK-4000; Vector Laboratories); and developed with 3,30-diaminoben-
zidine tetrahydrochloride (DAB) substrate (sub: cat. 11718096001;
Roche Diagnostics, Mannheim, Germany). Collagen fibers were evi-
denced by picrosirius red staining (cat. 365548; Sigma-Aldrich, St.
Louis, MO, USA). Images were acquired with the Pannoramic Desk
(3D Histech, Budapest, Hungary). The infiltrated area was measured
with Fiji software on hematoxylin-and-eosin-stained sections. Five
independent, 10 images per heart were randomly acquired and
quantified; the infiltrated area is expressed as percentage of total area.
Real-Time PCR
Total RNA was prepared with the Trizol protocol (cat. 15596026; In-
vitrogen, Carlsbad, CA, USA), RNA was treated with DNase, and
reverse transcription was performed with the High-Capacity cDNA
Reverse Transcription Kit, according to the manufacturer’s instruc-
tion (cat. 4368814; Applied Biosystems, Carlsbad, CA, USA). qRT-
PCR reactions were performed, as previously described, using the
Universal Probe Library system (Roche Diagnostics, Mannheim,
Germany) and Platinum Quantitative PCR SuperMix-UDG w/ROX
(cat. 11743500; Invitrogen, Carlsbad, CA, USA). Probes and oligonu-
cleotide sequences used are reported in the Table S1. The 18S rRNA
predeveloped TaqMan assay (cat. 4319413; Applied Biosystems,ber 2020
www.moleculartherapy.orgCarlsbad, CA, USA) was used as an internal control. PCR protocol is
50C for a 2-min hold, 95C for a 2-min hold, and 40 cycles of 95C,
15 s; 60C, 30 s.
Echocardiography
Echocardiography was performed in mice anesthetized with 1%
isoflurane with a Vevo2100 High-Resolution Imaging System (Vi-
sual Sonics, Toronto, ON, Canada) with the transducer MS550D
when heart rate was z450 beats per minute (bpm). Left-ventricle
end-systolic and left-ventricle end-diastolic (LVES and LVED,
respectively) diameters were measured with the 2D long-axis
left-ventricle M-mode. FS was calculated as (LVED  LVES)/
LVED%. EF was calculated using Doppler images as stroke vol-
ume/end-diastolic volume (SV/EDV), expressed as a percentage
at the indicated days after the first immunization. Results are
shown as mean ± SEM.
Statistics
Shapiro-Wilk normality test has been performed on all data and
nonparametric analysis (Mann-Whitney U test) used when needed
(Figures 1A and 2A). For normally distributed data, the unpaired
two-tailed Student’s t test with Welch’s correction was used for
comparisons between two groups of samples. Two-way ANOVA on
repeated measures with Bonferroni post-test was used for comparison
of group/time in all echocardiographic analyses. The log rankMantel-
Cox test was used for significance of survival curves. For all of the
experiments, mean values per group and corresponding intervals of
confidence were calculated and reported in Table S2 (experiments
in Figures 1, 2, and 3) and in Table S3 (experiments in Figures 4
and 5). All statistical analyses were performed with GraphPad Prim
7.0a (GraphPad Software). p values lower or equal to 0.05 were
considered significant.
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